CDMOs: Powering India’s Pharma Edge in the Global Supply Chain🌍💊
By combining end-to-end drug development with scaled manufacturing, they are pulling in global contracts, widening export footprints, and accelerating innovation — positioning India as an indispensable force in the world’s healthcare supply chain. 🏭
📊 India’s CDMO market, valued at ~USD 26 billion in 2028, is projected to surge past USD 44 billion by 2029—a testament to the country’s rapid global ascent 📈.
AIF Investor Charter 
NIVESHAAY INVESTMENT ADVISORS
508, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7859870559
research.smallcase@niveshaay.com (Equity Baskets)
NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED
610, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7836915478
contactaif@niveshaay.com (AIF)
SEBI Registration No. : INH000017338, IN/AIF3/24-25/1571, IN/AIF2/24-25/1607, INP000009506 | BASL Membership ID: 6276
Disclaimer:
Investment in Securities Market are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
The securities quoted are for illustration only and are not recommendatory
NIVESHAAY INVESTMENT ADVISORS © . All Rights Reserved., NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED © . All Rights Reserved.Smart ODR